| Revenue growth | 26.2% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin at 32% (37% excluding injectable facility and Stellon expenses). |
| Demand visibility | Strong, driven by increased business from existing customers and new acquisitions. |
| Management confidence | High; confident in outperforming industry growth and increasing wallet share. |
Growth
Revenue rose 26% YoY to ₹257.5 Cr; EBITDA grew 34% to ₹82.4 Cr with margins expanding 190 bps.
Outlook
Targeting 2-3 product launches annually; focus on injectable facility ramp-up and leveraging new approvals from ANVISA, PPB, and NDA.
Risks
Formulation revenue declined 23% YoY; regulatory compliance remains critical across diverse global manufacturing inspections.
Last quarter's promises, checked
Delivered
- Guided historical growth ~18% → delivered 26.2% (= BEAT)
- Guided API revenue growth → delivered 42% (= BEAT)
- Guided export recovery → delivered 46% surge (= BEAT)
Partly delivered
- Guided EBITDA margin 39-40% (adj.) → delivered 37% (adj.) (= PARTIAL)
Missed
- Guided formulation business recovery → delivered -23% YoY (= MISS)
Investor Presentation filed with BSE, NSE: CONCORDBIO. Summary written with AI assistance from the document.
Concord Biotech Ltd: key numbers
- Share price
- ₹1,453.60
- Market cap
- ₹15,207 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 55.2×Sector 50.4×
- Promoter holding
- 44.08%+0.00% QoQ
- FII holding
- 7.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Bonus Issue
Concord Biotech's board recommended a 1:1 bonus share issue from free reserves. Shareholders will consider this proposal at an upcoming postal ballot on October 24, 2026.
Concord Biotech Bonus Issue
Concord Biotech approved a 1:1 bonus issue of 10.46 crore equity shares. The board also increased the company's authorized share capital to Rs. 22 Crore.
- Value
- ₹10.46 Cr
Concord Biotech Board Meeting Date
Concord Biotech Ltd announced a board meeting for September 23, 2026, to consider a proposal for the declaration of bonus equity shares.
Concord Biotech Business Update
Concord Biotech disclosed a successful USFDA inspection at its Valthera facility with one minor non-GMP observation. No material impact on operations or existing supplies is expected.
Concord Biotech Earnings Call Transcript: Key Takeaways
Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.
Concord Biotech Q1 FY27 Results: Net Profit ₹57.7 Cr, Up 30.8% YoY
Concord Biotech Ltd reported revenue from operations of ₹257.5 Cr (+26.2% YoY) and net profit of ₹57.7 Cr (+30.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹57.7 Cr · +30.8% YoY